Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9377)
All Articles published online
|
Publishing Process of This Article
|
Nov 14, 2015 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12059-12070 [PMID: 26576091 DOI: 10.3748/wjg.v21.i42.12059] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v21/i42/12059.htm |
| Number | Citing Articles |
| 1 |
Yang Hai, Jia-Jia Geng, Peng-Jie Li, Wei-Ping Ma, Cui-Fang Wang, Mei-Yan Wei, Xue-Mei Hou, Guang-Ying Chen, Yu-Cheng Gu, Ming Liu, Chang-Lun Shao. Semisynthesis and biological evaluation of (+)-sclerotiorin derivatives as antitumor agents for the treatment of hepatocellular carcinoma. European Journal of Medicinal Chemistry 2022; 232: 114166 doi: 10.1016/j.ejmech.2022.114166
|
| 2 |
Bijay Dhungel, Charmaine A. Ramlogan-Steel, Christopher J. Layton, Jason C. Steel. MicroRNA199a-Based Post-transcriptional Detargeting of Gene Vectors for Hepatocellular Carcinoma. Molecular Therapy - Nucleic Acids 2018; 13: 78 doi: 10.1016/j.omtn.2018.08.016
|
| 3 |
Bahareh Farasati Far, Mohammad Reza Naimi-Jamal, Hossein Daneshgar, Navid Rabiee. Co-delivery of doxorubicin/sorafenib by DNA-decorated green ZIF-67-based nanocarriers for chemotherapy and hepatocellular carcinoma treatment. Environmental Research 2023; 225: 115589 doi: 10.1016/j.envres.2023.115589
|
| 4 |
Gundula Streubel, Sabine Schrepfer, Hannah Kallus, Ulrike Parnitzke, Tanja Wulff, Frank Hermann, Matthias Borgmann, Svetlana Hamm. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-88983-1
|
| 5 |
Liyu Shi, Xiaoqiu Zheng, Yuzhuo Fan, Xiaolan Yang, Aimei Li, Jun Qian. The contribution of miR-122 to the innate immunity by regulating toll-like receptor 4 in hepatoma cells. BMC Gastroenterology 2019; 19(1) doi: 10.1186/s12876-019-1048-3
|
| 6 |
Menelaos Zafrakas, Panayiota Papasozomenou, Christos Emmanouilides. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World Journal of Clinical Oncology 2016; 7(4): 331-336 doi: 10.5306/wjco.v7.i4.331
|
| 7 |
MK Morris, DC Clarke, LC Osimiri, DA Lauffenburger. Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling Networks. CPT: Pharmacometrics & Systems Pharmacology 2016; 5(10): 544 doi: 10.1002/psp4.12104
|
| 8 |
Maximilian A. Ardelt, Thomas Fröhlich, Emanuele Martini, Martin Müller, Veronika Kanitz, Carina Atzberger, Petra Cantonati, Martina Meßner, Laura Posselt, Thorsten Lehr, Jan‐Georg Wojtyniak, Melanie Ulrich, Georg J. Arnold, Lars König, Dario Parazzoli, Stefan Zahler, Simon Rothenfußer, Doris Mayr, Alexander Gerbes, Giorgio Scita, Angelika M. Vollmar, Johanna Pachmayr. Inhibition of Cyclin‐Dependent Kinase 5. Hepatology 2019; 69(1): 376 doi: 10.1002/hep.30190
|
| 9 |
Liping Zhu, Min Wu, Peng Li, Yanfei Zhou, Jinyi Zhong, Zhiqiang Zhang, Ye Li, Weixi Yao, Jianhua Xu. High-Pressure Supercritical CO2 Extracts of Ganoderma lucidum Fruiting Body and Their Anti-hepatoma Effect Associated With the Ras/Raf/MEK/ERK Signaling Pathway. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.602702
|
| 10 |
Min Yang, Jingtao Liu, Fei Wang, Zhihua Tian, Bo Ma, Zhongwu Li, Boqing Wang, Wei Zhao. Lysyl oxidase assists tumor‑initiating cells to enhance angiogenesis in hepatocellular carcinoma. International Journal of Oncology 2019; doi: 10.3892/ijo.2019.4705
|
| 11 |
Xin Lu, Zhiyuan Chen, Wenting Mi, Jianming Zheng, Yubin Liu. MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE. Open Medicine 2024; 19(1) doi: 10.1515/med-2024-1060
|
| 12 |
Beste Yurdacan, Unal Egeli, Gamze Guney Eskiler, Isil Ezgi Eryilmaz, Gulsah Cecener, Berrin Tunca. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid. Journal of Pharmacy and Pharmacology 2019; 71(7): 1119 doi: 10.1111/jphp.13097
|
| 13 |
Alanoud Altalal, Aliyah Almomen, Musaed Alkholief, Ziyad Binkhathlan, Nourah Z. Alzoman, Aws Alshamsan. Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats. Saudi Pharmaceutical Journal 2023; 31(7): 1317 doi: 10.1016/j.jsps.2023.05.025
|
| 14 |
Sara Jaramillo, Francisco J.G. Muriana, Rafael Guillen, Ana Jimenez-Araujo, Rocio Rodriguez-Arcos, Sergio Lopez. Saponins from edible spears of wild asparagus inhibit AKT, p70S6K, and ERK signalling, and induce apoptosis through G0/G1 cell cycle arrest in human colon cancer HCT-116 cells. Journal of Functional Foods 2016; 26: 1 doi: 10.1016/j.jff.2016.07.007
|
| 15 |
Zhengguang Zhang, Cunsi Shen, Fuqiong Zhou. The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death. Medical Oncology 2022; 39(12) doi: 10.1007/s12032-022-01797-7
|
| 16 |
Francesca Mastropasqua, Flaviana Marzano, Alessio Valletti, Italia Aiello, Giuseppe Di Tullio, Annalisa Morgano, Sabino Liuni, Elena Ranieri, Luisa Guerrini, Giuseppe Gasparre, Elisabetta Sbisà, Graziano Pesole, Antonio Moschetta, Mariano Francesco Caratozzolo, Apollonia Tullo. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours. Molecular Cancer 2017; 16(1) doi: 10.1186/s12943-017-0634-7
|
| 17 |
Ming-Hua Hsu, Shih-Ming Hsu, Yu-Cheng Kuo, Chih-Yu Liu, Cheng-Ying Hsieh, Yuh-Ching Twu, Chung-Kwe Wang, Yuan-Hsi Wang, Yi-Jen Liao. Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancer. RSC Advances 2017; 7(26): 16253 doi: 10.1039/C6RA28281D
|
| 18 |
Negin Chaeichi-Tehrani, Gordon A. Ferns, Seyed Mahdi Hassanian, Majid Khazaei, Amir Avan. The Therapeutic Potential of Targeting Autophagy in the Treatment of Cancer. Current Cancer Drug Targets 2021; 21(9): 725 doi: 10.2174/1568009621666210601113144
|
| 19 |
Maurizio Biselli, Nicola Reggidori, Massimo Iavarone, Matteo Renzulli, Lorenzo Lani, Alessandro Granito, Fabio Piscaglia, Stefania Lorenzini, Eleonora Alimenti, Giulio Vara, Paolo Caraceni, Angelo Sangiovanni, Massimo Marignani, Elia Gigante, Nicolò Brandi, Annagiulia Gramenzi, Franco Trevisani. Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers 2024; 16(6): 1080 doi: 10.3390/cancers16061080
|
| 20 |
Ahmed A. H. Abdellatif, Asmaa T. Ali, Abdellatif Bouazzaoui, Mansour Alsharidah, Osamah Al Rugaie, Nahla Sameh Tolba. Formulation of polymeric nanoparticles loaded sorafenib; evaluation of cytotoxicity, molecular evaluation, and gene expression studies in lung and breast cancer cell lines. Nanotechnology Reviews 2022; 11(1): 987 doi: 10.1515/ntrev-2022-0058
|
| 21 |
Alaa Elmetwalli, Mohamed O. Abdel-Monem, Ali H. El-Far, Gehad S. Ghaith, Noaf Abdullah N. Albalawi, Jihan Hassan, Nadia F. Ismail, Tarek El-Sewedy, Mashael Mashal Alnamshan, Nouf K. ALaqeel, Ibtesam S. Al-Dhuayan, Mervat G. Hassan. Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment. Medical Oncology 2024; 41(5) doi: 10.1007/s12032-024-02330-8
|
| 22 |
Israr Fatima, Abdur Rehman, Yanheng Ding, Peng wang, Yuxuan Meng, Hafeez Ur Rehman, Dawood Ahmad Warraich, Zhibo Wang, Lijun Feng, Mingzhi Liao. Breakthroughs in AI and multi-omics for cancer drug discovery: A review. European Journal of Medicinal Chemistry 2024; 280: 116925 doi: 10.1016/j.ejmech.2024.116925
|
| 23 |
Peter Dietrich, Andreas Koch, Valerie Fritz, Arndt Hartmann, Anja Katrin Bosserhoff, Claus Hellerbrand. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut 2018; 67(7): 1328 doi: 10.1136/gutjnl-2017-315402
|
| 24 |
Peter Dietrich, Kim Freese, Abdo Mahli, Wolfgang Erwin Thasler, Claus Hellerbrand, Anja Katrin Bosserhoff. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option. Oncotarget 2018; 9(3): 3605 doi: 10.18632/oncotarget.23188
|
| 25 |
Mi Hou, Ya‐Yu Zou, Si‐Li Fan, Xiao‐Qin Li, Li‐Hui Shao, Zhu‐Rui Li, Dan‐Ping Chen, Zhen‐Chao Wang, Gui‐Ping Ouyang. Design, synthesis, and antitumor activity of novel sorafenib derivatives. Journal of Heterocyclic Chemistry 2022; 59(6): 1025 doi: 10.1002/jhet.4440
|
| 26 |
Alicia Bort, Elena Spínola, Nieves Rodríguez-Henche, Inés Díaz-Laviada. Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation. Oncotarget 2017; 8(50): 87684 doi: 10.18632/oncotarget.21196
|
| 27 |
Shuzhen Chen, Qiqi Cao, Wen Wen, Hongyang Wang. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Letters 2019; 460: 1 doi: 10.1016/j.canlet.2019.114428
|
| 28 |
Guirong Zheng, Ruirui Zhao, Aixiao Xu, Zhichun Shen, Xian Chen, Jingwei Shao. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. European Journal of Pharmaceutical Sciences 2018; 111: 492 doi: 10.1016/j.ejps.2017.10.036
|
| 29 |
Amna Mohamed Taha, Mohammad Mabrouk Aboulwafa, Hamdallah Zedan, Omneya Mohamed Helmy. Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-21582-w
|
| 30 |
Chang-Jiang Lei, Jia-Ni Liu, Rong Wu, Zhi-Xiong Long, Jiang-Zhou Zhang, Dan Tao, Yan-Ping Liu. Change of the peripheral blood immune pattern and its correlation with prognosis in patients with liver cancer treated by sorafenib. Asian Pacific Journal of Tropical Medicine 2016; 9(6): 592 doi: 10.1016/j.apjtm.2016.04.019
|
| 31 |
Hongyong Zhang, Yufeng Wang, Yanxia Bai, Yuan Shao, Jigang Bai, Zhenhua Ma, Qingguang Liu, Shengli Wu. Recombinant adeno-associated virus expressing a p53-derived apoptotic peptide (37AA) inhibits HCC cells growth in vitro and in vivo. Oncotarget 2017; 8(10): 16801 doi: 10.18632/oncotarget.15160
|
| 32 |
Seung Un Seo, Seon Min Woo, Seung-Soon Im, Younghoon Jang, Eugene Han, Sang Hyun Kim, Hongchan Lee, Hyun-Shik Lee, Ju-Ock Nam, Edward Gabrielson, Kyoung-jin Min, Taeg Kyu Kwon. Cathepsin D as a potential therapeutic target to enhance anticancer drug-induced apoptosis via RNF183-mediated destabilization of Bcl-xL in cancer cells. Cell Death & Disease 2022; 13(2) doi: 10.1038/s41419-022-04581-7
|
| 33 |
Shanshan Jiang, Qian Wang, Meiqing Feng, Jiyang Li, Zhongbin Guan, Duopeng An, Mengxue Dong, Yuzhe Peng, Kudelaidi Kuerban, Li Ye. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. Applied Microbiology and Biotechnology 2017; 101(4): 1535 doi: 10.1007/s00253-016-7930-9
|
| 34 |
Diego Almanza, Mehrnaz Gharaee-Kermani, Alisa Zhilin-Roth, Jose A. Rodriguez-Nieves, Cory Colaneri, Todd Riley, Jill A. Macoska. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature. Digestive Diseases and Sciences 2019; 64(5): 1257 doi: 10.1007/s10620-018-5398-4
|
| 35 |
Mohammed K. AbdElhameid, Madlen B. Labib, Ahmed T. Negmeldin, Muhammad Al-Shorbagy, Manal R. Mohammed. Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 2018; 33(1): 1472 doi: 10.1080/14756366.2018.1503654
|
| 36 |
Thanaa A. El-Masry, Maysa M. F. El-Nagar, Nageh A. El Mahdy, Fatemah A. Alherz, Reham Taher, Enass Y. Osman. Potential Antitumor Activity of Combined Lycopene and Sorafenib against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation. Pharmaceuticals 2024; 17(4): 527 doi: 10.3390/ph17040527
|
| 37 |
Fang Wang, Thomas Bank, Gregory Malnassy, Maribel Arteaga, Na Shang, Annika Dalheim, Xianzhong Ding, Scott J. Cotler, Mitchell F. Denning, Michael I. Nishimura, Peter Breslin, Wei Qiu. Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. Hepatology Communications 2018; 2(6): 732 doi: 10.1002/hep4.1181
|
| 38 |
Zibo Chen, Tao Yuan, Fangjie Yan, Song Ye, Qin Xie, Bo Zhang, Nengmin Lin, Qiaojun He, Bo Yang, Hong Zhu. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09520-5
|
| 39 |
Tian-yi Zhou, Lin-han Zhuang, Yan Hu, Yu-lu Zhou, Wen-kai Lin, Dan-dan Wang, Zi-qian Wan, Lin-lin Chang, Ying Chen, Mei-dan Ying, Zi-bo Chen, Song Ye, Jian-shu Lou, Qiao-jun He, Hong Zhu, Bo Yang. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Scientific Reports 2016; 6(1) doi: 10.1038/srep30483
|
| 40 |
Ao Huang, Xin-Rong Yang, Wen-Yuan Chung, Ashley R. Dennison, Jian Zhou. Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-00264-x
|
| 41 |
Xueyao Wang, Rui Hu, Zhenwei Song, Huajun Zhao, Zhaoyi Pan, Yujie Feng, Yating Yu, Qiuju Han, Jian Zhang. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity. Cancer Letters 2022; 547: 215880 doi: 10.1016/j.canlet.2022.215880
|
| 42 |
Yaoye Tao, Jianguo Wang, Xiao Xu. Emerging and Innovative Theranostic Approaches for Mesoporous Silica Nanoparticles in Hepatocellular Carcinoma: Current Status and Advances. Frontiers in Bioengineering and Biotechnology 2020; 8 doi: 10.3389/fbioe.2020.00184
|
| 43 |
Rui Zhang, Min Ma, Gang Dong, Rong‐Rong Yao, Jing‐Huan Li, Qiong‐Dan Zheng, Yin‐Ying Dong, Hui Ma, Dong‐Mei Gao, Jie‐Feng Cui, Zheng‐Gang Ren, Rong‐Xin Chen. Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment. Cancer Science 2017; 108(9): 1778 doi: 10.1111/cas.13322
|
| 44 |
Lei Jiang, Luan Li, Yongzhuang Liu, Meixiao Zhan, Ligong Lu, Shengtao Yuan, Yanyan Liu. Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1097277
|
| 45 |
Bilal Rah, Rafiq A Rather, Gh Rasool Bhat, Abdul Basit Baba, Ifra Mushtaq, Muzamil Farooq, Tahira Yousuf, Sadaf B Dar, Sabra Parveen, Rukhsana Hassan, Fozia Mohammad, Iqbal Qassim, Abida Bhat, Shazia Ali, Mahrukh Hamid Zargar, Dil Afroze. JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.821344
|
| 46 |
Zhuona Rong, Tingting Fan, Huiling Li, Juan Li, Kangwei Wang, Xinxin Wang, Jianyi Dong, Jun Chen, Fujin Wang, Jingyu Wang, Aiguo Wang. Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic Mice. Molecular & Cellular Proteomics 2017; 16(8): 1475 doi: 10.1074/mcp.M116.065474
|
| 47 |
Kangnan Zhang, Qinghui Zhang, Rongrong Jia, Shihao Xiang, Ling Xu. A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy. Frontiers in Cell and Developmental Biology 2023; 11 doi: 10.3389/fcell.2023.1156383
|
| 48 |
Shunnan Yao, Jianpin Ye, Mengqi Yin, Rui Yu. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. Cancer Letters 2020; 483: 87 doi: 10.1016/j.canlet.2020.04.003
|
| 49 |
Zijian Wang, Chunyang Zhou, Yiming Zhang, Xinchen Tian, Haochen Wang, Jibiao Wu, Shulong Jiang. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2024; 170: 116074 doi: 10.1016/j.biopha.2023.116074
|
| 50 |
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang. Genetic alterations in hepatocellular carcinoma: An update. World Journal of Gastroenterology 2016; 22(41): 9069-9095 doi: 10.3748/wjg.v22.i41.9069
|
| 51 |
Jing Li, Jinfeng Wang, Wei Zhou, Shuqin Zhang, Yuan Le, Rong He. Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells. Oncology Letters 2017; 14(4): 4751 doi: 10.3892/ol.2017.6770
|